Two mission-driven organisations based at Leiden Bio Science Park have joined forces to improve access to life-saving cell and gene therapies. NecstGen and the World Marrow Donor Association (WMDA) have announced a strategic partnership that brings together complementary expertise in manufacturing and donor services.
NecstGen, a centre for advanced therapy development and GMP manufacturing, will collaborate with WMDA, which operates a global donor network and leads efforts in donor recruitment, matching and care. Both organisations are non-profit and deeply committed to improving patient outcomes.
“Cellular therapy starts with high-quality cells from donors who are protected,” says Lydia Foeken-van Goozen, CEO of WMDA. “We believe that our collaboration with NecstGen will benefit both patients and donors.”
By combining capabilities, the partnership aims to accelerate innovation in cell and gene therapy, address challenges in scaling up manufacturing, and improve pathways for both patients and donors. The focus is on practical, sustainable solutions that uphold the highest quality and safety standards.
“We are excited about the road ahead and will share further updates as our joint effort progresses,” says Tristan Pritchard-Meaker, Head of Business Development at NecstGen.
As part of the thriving life sciences ecosystem in Leiden, this partnership reflects the power of collaboration within the Bio Science Park community. Together, NecstGen and WMDA will work to make advanced therapies more accessible and impactful for patients worldwide.
